Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$12.43 USD
+1.45 (13.21%)
Updated Sep 9, 2024 10:04 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Travere Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 567 | 450 | 553 | 362 | 399 |
Receivables | 21 | 17 | 16 | 33 | 18 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 9 | 7 | 7 | 8 | 6 |
Other Current Assets | 19 | 13 | 6 | 8 | 6 |
Total Current Assets | 617 | 486 | 583 | 410 | 429 |
Net Property & Equipment | 7 | 9 | 11 | 9 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 104 | 145 | 148 | 154 | 158 |
Deposits & Other Assets | 42 | 11 | 11 | 33 | 15 |
Total Assets | 789 | 673 | 777 | 607 | 605 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 42 | 17 | 15 | 12 | 27 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 119 | 96 | 75 | 57 | 52 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 25 | 30 | 24 | 17 |
Total Current Liabilities | 178 | 142 | 124 | 93 | 95 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 11 | 20 | 0 | 0 |
Convertible Debt | 377 | 376 | 227 | 215 | 205 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 74 | 72 | 88 | 83 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 588 | 630 | 475 | 396 | 384 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,328 | 1,060 | 1,069 | 798 | 637 |
Retained Earnings | -1,126 | -1,014 | -766 | -586 | -416 |
Other Equity | -1 | -3 | -1 | -1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 201 | 43 | 302 | 211 | 221 |
Total Liabilities & Shareholder's Equity | 789 | 673 | 777 | 607 | 605 |
Total Common Equity | 201 | 43 | 302 | 211 | 221 |
Shares Outstanding | 75.10 | 64.10 | 61.20 | 51.00 | 42.90 |
Book Value Per Share | 2.67 | 0.67 | 4.94 | 4.14 | 5.16 |
Fiscal Year End for Travere Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 325 | 441 | 567 | 635 | 491 |
Receivables | 24 | 23 | 21 | 15 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 5 | 9 | 21 | 19 |
Other Current Assets | 13 | 13 | 19 | 16 | 12 |
Total Current Assets | 369 | 481 | 617 | 686 | 542 |
Net Property & Equipment | 7 | 7 | 7 | 8 | 9 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 105 | 101 | 104 | 107 | 154 |
Deposits & Other Assets | 54 | 57 | 42 | 13 | 12 |
Total Assets | 551 | 664 | 789 | 833 | 736 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 17 | 42 | 25 | 20 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 80 | 140 | 119 | 96 | 89 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 12 | 12 | 14 | 22 |
Total Current Liabilities | 121 | 173 | 178 | 139 | 136 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 1 | 2 | 5 | 7 |
Convertible Debt | 378 | 378 | 377 | 377 | 376 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 17 | 8 | 8 | 76 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 536 | 589 | 588 | 553 | 620 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,349 | 1,338 | 1,328 | 1,319 | 1,307 |
Retained Earnings | -1,332 | -1,262 | -1,126 | -1,035 | -1,186 |
Other Equity | -2 | -2 | -1 | -4 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 15 | 74 | 201 | 280 | 116 |
Total Liabilities & Shareholder's Equity | 551 | 664 | 789 | 833 | 736 |
Total Common Equity | 15 | 74 | 201 | 280 | 116 |
Shares Outstanding | 76.40 | 76.10 | 75.10 | 75.00 | 74.60 |
Book Value Per Share | 0.20 | 0.97 | 2.67 | 3.73 | 1.56 |